antioxidants
Review
Oxidative Stress in Type 2 Diabetes: The Case for Future
Pediatric Redoxomics Studies
Stephanie N. Alu, Evan A. Los, George A. Ford and William L. Stone *
Department of Pediatrics, Quillen College of Medicine, Johnson City, TN 37614, USA; alusn1@etsu.edu (S.N.A.);
losea1@etsu.edu (E.A.L.); fordga@etsu.edu (G.A.F.)
* Correspondence: stone@etsu.edu; Tel.: +1-423-439-8762
Citation: Alu, S.N.; Los, E.A.; Ford,
G.A.; Stone, W.L. Oxidative Stress in
Type 2 Diabetes: The Case for Future
Pediatric Redoxomics Studies.
Antioxidants 2022, 11, 1336. https://
Abstract: Considerable evidence supports the role of oxidative stress in adult type 2 diabetes (T2D).
Due to increasing rates of pediatric obesity, lack of physical activity, and consumption of excess food
calories, it is projected that the number of children living with insulin resistance, prediabetes, and
T2D will markedly increase with enormous worldwide economic costs. Understanding the factors
contributing to oxidative stress and T2D risk may help develop optimal early intervention strategies.
Evidence suggests that oxidative stress, triggered by excess dietary fat consumption, causes excess
mitochondrial hydrogen peroxide emission in skeletal muscle, alters redox status, and promotes
insulin resistance leading to T2D. The pathophysiological events arising from excess calorie-induced
mitochondrial reactive oxygen species production are complex and not yet investigated in children.
Systems medicine is an integrative approach leveraging conventional medical information and
environmental factors with data obtained from “omics” technologies such as genomics, proteomics,
and metabolomics. In adults with T2D, systems medicine shows promise in risk assessment and
predicting drug response. Redoxomics is a branch of systems medicine focusing on “omics” data
related to redox status. Systems medicine with a complementary emphasis on redoxomics can
potentially optimize future healthcare strategies for adults and children with T2D.
Keywords: redoxomics; diabetes; oxidative stress; antioxidants; insulin resistance; skeletal muscle;
glucose
doi.org/10.3390/antiox11071336
Academic Editors: Jiankang Liu,
Maria Cristina Albertini,
Yoko Ozawa, Dov Lichtenberg
and Serkos A. Haroutounian
Received: 4 May 2022
Accepted: 30 June 2022
Published: 7 July 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1. Introduction
About one in ten, or 37 million Americans, have diabetes mellitus (DM), with an
annual estimated cost (in 2017) of $237 billion [1,2]. About 90–95% of Americans with
DM have type 2 (T2D), which usually develops after age 45 but is rapidly increasing in
pediatric patients as young as 4 years old. The overall rate of T2D in the U.S. is 8.1 per
100,000 in children aged 10–14 and 11.8 per 100,000 in adolescents aged 15–19. The highest
rates are among Native American Indians [3,4]. However, the most startling statistic is
that 1 in 5 adolescents are currently living with prediabetes [5]. Prediabetes dramatically
increases the risk of developing T2D and other complications such as kidney or heart
disease [5,6]. The projected prevalence of T2D in the pediatric population is estimated to
increase by 49% over the next few decades [7]. Earlier development of T2D in youths will
likely result in diabetes-related complications occurring at a younger age with a decreased
life expectancy and markedly increased healthcare costs.
As outlined in Figure 1, it is now generally accepted that T2D progresses in four stages,
i.e., insulin resistance, prediabetes, T2D, and T2D with vascular complications [8,9]. In
keeping with our focus on pediatric T2D, we will emphasize the first three stages and the
potential etiological role of oxidative stress. As detailed below, dietary-induced oxidative
stress is a likely early initiating factor for insulin resistance and, therefore, particularly
important in childhood progression to T2D. Early intervention to prevent dietary-induced
oxidative stress may help delay or prevent the progression to T2D [10]. The past, current,
Antioxidants 2022, 11, 1336. https://doi.org/10.3390/antiox11071336
https://www.mdpi.com/journal/antioxidants
Antioxidants 2022, 11, 1336
2 of 17
and future role of oxidative stress in T2D will be summarized. A future systems medicine
approach (detailed in Section 3), with a complementary emphasis on redoxomics, may
provide early risk assessment and help guide healthcare strategies. Redoxomics, with its
comprehensive focus on oxidative stress-health risk factors, holds promise for preventing,
treating, and monitoring T2D [11].
Figure 1. The stages of Type 2 Diabetes (T2D). Chronic excess calories produce skeletal muscle
mitochondria reactive oxygen species (ROS) emission, which, along with dietary AGEs, initiates
insulin resistance and contributes to postprandial oxidative stress. Insulin resistance and the resulting
hyperglycemia activate the polyol pathway with additional AGE-formation that amplifies oxidative
stress/inflammation and contributes to beta-cell dysfunctions. Skeletal muscle ROS formation and
postprandial oxidative stress will continue to act deleteriously throughout all four stages of T2D (long
blue arrow) unless treated with lifestyle and medical interventions. High levels of dietary AGEs and
low levels of dietary antioxidants will also contribute to postprandial oxidative stress and accelerate
T2D progression.
1.1. Obesity, Lack of Physical Activity, Poor Diet, and Insulin Resistance Are Major Risk Factors
for Pediatric T2D
Major risk factors for pediatric T2D include overweight, obesity, a lack of physical
activity, a poor diet, and insulin resistance [4,12]. Moreover, pediatric T2D is associated
with increased plasma levels of free fatty acids (FFAs), primarily caused by an increased
fat mass [13]. Frohnert et al. [13] found that the relationship between FFAs and insulin
resistance is not significant in early adolescence but becomes so in young adulthood.
1.2. The Role of Postprandial Oxidative Stress (POS) in T2D
In a prescient 2006 article, Wright et al. reviewed the evidence supporting the role of
postprandial oxidative stress (POS) as a “root cause” of T2D [14]. These authors summarized the links between excess dietary calories and POS and the resulting insulin resistance
and eventual beta-cell dysfunction. They also emphasized the potential role of postprandial
hyperglycemia in promoting the formation of plasma-advanced glycation end products
as astress
“root
cause” of T2D
(AGEs), increasing oxidative
and inflammation
and reducing nitric oxide (NO) availability. Since 2006 there has been considerable new evidence supporting the role of POS in
T2D [15]. We now know that excess dietary fat is much more significant than appreciated in
2006. As detailed below, excess dietary fat promotes skeletal muscle mitochondrial-induced
oxidative stress leading to insulin resistance [16]. As indicated in Figure 1, plasma-POS
likely reflects both dietary pro-oxidant/antioxidant factors as well as skeletal muscle
mitochondrial-induced oxidative stress and dietary AGEs [17–19].
1.3. Dietary Fat Level Is a Key Determinant of Plasma-POS
Direct observations in human plasma samples indicate that shortly after food ingestion,
there is a transient increase in the production of reactive oxygen species (ROS) and a
Antioxidants 2022, 11, 1336
3 of 17
simultaneous decrease in antioxidants [20]. Bloomer et al. compared plasma POS in healthy
young male adults after consuming isocaloric amounts of carbohydrate (dextrose) or lipid
(heavy whipping cream) [20]. Dietary fat generated more POS than dietary carbohydrates.
As expected, blood glucose significantly increased after the carbohydrate meals but not
after the lipid meals. Sottero et al. suggest that POS is exacerbated in T2D due to AGEs and
increased plasma levels of FFAs (aka hypernefemia) [15].
1.4. Dietary Fat Type and Dietary Antioxidants Influence Plasma-POS
The type of dietary fat has also been shown to play a role in plasma POS with a high
level of monounsaturated fatty acid (MUFA) causing less oxidative stress than a high level
of saturated fatty acid (SFA) [21,22]. The MUFA content of the Mediterranean diet is high
and, when compared to a diet high in SFA, improves POS, nitric oxide (NO) levels, and
capillary flow in the elderly [22]. Recent evidence shows the Mediterranean diet to be
beneficial for T2D and prediabetes [23,24]. The Mediterranean diet, which is also high
in polyphenolic antioxidants, increases endogenous antioxidant activity and decreases
pro-oxidant activity [25]. In obese children or adolescents, a Mediterranean diet improves
body mass index (BMI) as well as glucose and lipid profiles [26]. Supplementing a high
SFA meal with a pool of antioxidants reduces POS and improves endothelial function in
both normal and insulin-resistant subjects [17].
The measurement of plasma POS parameters in the pediatric population may prove to
be of clinical relevance. As indicated in Figure 1, excess dietary fat-induced mitochondrial
oxidative stress in skeletal muscle is an underlying initial cause of insulin resistance. We
will next summarize the pathophysiology of T2D, emphasizing the role of oxidative stress.
The key molecular players discussed below are also probable candidates to be measured in
future pediatric redoxomics studies.
2. The Pathophysiology of T2D
T2D is a complex disease involving multiple organ systems with numerous alterations
in carbohydrate, protein, and lipid biochemistry. This complexity continues at the cellular
level with the involvement of multiple subcellular organelles. A comprehensive review of
the pathophysiological mechanisms underlying T2D is beyond the scope of this review. A
concise summary of oxidative stress, ROS, and antioxidants can be found online [27]. Given
the importance of glucose and insulin in T2D, we will briefly outline their key normal
and pathophysiological roles [28]. Intracellular glucose oxidation is a primary source of
energy for producing ATP. Energy metabolism, in turn, is highly linked to the production
of ROS [29].
Glucose transport from the circulation into tissues is primarily governed by four facilitative transporters, i.e., GLUT1, GLUT2, GLUT3, and GLUT4, each with a physiologically
relevant Km (Michaelis constant) and Vmax (reaction rate when the transporter/enzyme
is fully saturated by substrate). GLUT1 is highly expressed on red blood cells, is insulinindependent, and rapidly equilibrates RBC cytoplasmic glucose with plasma glucose.
Endothelial cells also rely on GLUT1 for glucose transport [30]. GLUT4 is an insulinresponsive transporter and is present in the cells of skeletal muscle, heart, liver, and
adipose tissue. Skeletal muscle primarily utilizes GLUT4 but may also express low levels
of GLUT1 [31,32]. Insulin release from the beta-cells of the pancreatic islets of Langerhans
is normally triggered by a postprandial increase in plasma glucose. Insulin binding to the
insulin receptor (IR) on sensitive cells results in the activation (by phosphorylation) of the
AKT protein, which is a serine/threonine-specific protein kinase. AKT phosphorylation, in
turn, results in the translocation of GLUT4 to the plasma membrane and thereby increasing
the level of glucose transport [33]. When blood levels of insulin are high, skeletal muscle
accounts for about 70–80% of total glucose uptake in healthy young adults [34].
Insulin resistance is the decreased ability of a given dose of insulin to increase glucose
uptake from an individual’s circulation compared to the normal nondiabetic population [35].
Skeletal muscle insulin resistance is considered the primary defect in T2D [34]. In the pre-
Antioxidants 2022, 11, 1336
4 of 17
diabetic state, there is resistance to insulin action and an initial compensatory increase
in beta-cell insulin secretion to maintain normal plasma glucose levels. This initial compensatory hyperinsulinemia is generally viewed as beneficial in the prediabetic state, but
chronic glucose exposure is thought to promote eventual beta-cell failure with a resulting
T2D. Although beyond the scope of this review, there is also evidence that hyperinsulinemia
could contribute to T2D progression and pathophysiology [36]. It has been suggested that
hyperinsulinemia may play a role in promoting oxidative stress in T2D, but further study
is needed [37]. In an animal model (Wistar rats), short-term hyperinsulinemia reduces
oxidative stress [38].
2.1. Skeletal Muscle Insulin Resistance Is a Primary Defect in T2D
Skeletal muscle utilizes both fatty acids and glucose as energy sources to produce ATP.
Fatty acids are the primary fuel utilized during rest or mild-intensity exercise, whereas
glucose consumption dominates with high-intensity exercise. Under aerobic conditions,
pyruvate (from glucose metabolism) can be oxidized by mitochondria, but under anaerobic
conditions, pyruvate generates ATP by glycolysis in the cytoplasm. In contrast, fatty acids
are utilized only by mitochondria to produce ATP. As mentioned above, skeletal muscle
uptake of glucose from the capillary circulation is primarily regulated by the GLUT4 transporter [32]. Exercise and insulin delivery promote glucose transport to muscle but do so
through distinct molecular mechanisms that act synergistically [32]. Under hyperglycemic
conditions, T2D patients show impaired insulin-stimulated glucose transport into skeletal
muscle and decreased intramuscular levels of glucose-6-phosphate (G-6P) compared to
normal subjects with the same plasma glucose levels [39,40]. G-6P is a key metabolite for
maintaining cellular redox homeostasis [41]. Work by Ciaraldi et al. shows that skeletal
muscle GLUT1 expression in T2D is reduced compared to age-matched nondiabetics and
that glucose uptake into leg skeletal muscle is reduced in T2D [31].
2.2. Skeletal Muscle Glutathione Peroxidase System and Oxidative Stress
As shown in Figure 2, glucose is converted to G-6P by hexokinase (HK) and G-6P
is a substrate for glucose-6-phosphate dehydrogenase (G6PD), which is an antioxidant
enzyme that reduces nicotinamide adenine dinucleotide phosphate (NADP+ ) to NADPH.
This reduction reaction is the first step in the pentose phosphate pathway (PPP) which
plays a central role in DM [42]. Intracellular NADPH is essential for reducing oxidized
glutathione (GSSG) to reduced glutathione (GSH) which is the main intracellular watersoluble chemical antioxidant. This reaction is catalyzed by GSH reductase (GR). GSH is a
tripeptide (gamma-glutamyl-cysteinyl glycine) and a substrate for glutathione peroxidase
(GPX), which reduce H2 O2 to water (or lipid hydroperoxides to lipid alcohols) with the
formation of oxidized GSH (GSSG) [27,43]. GPX, in concert with GSH, prevents oxidative
stress by reducing levels of H2 O2 , which is a ROS. The decreased intramuscular level of
G-6P seen in T2D is, therefore, a likely contributor to oxidative stress by inhibiting NADPHdependent GSH recycling. G6PD activity in adult T2D patients is negatively correlated
with oxidative stress biomarkers and HbA1c levels [44]. Moreover, G6PD deficiency has
been linked with T2D [45]. G6PD deficiency is one of the most common forms of genetic
enzyme deficiency.
GPXs are a family of enzymes, with GPX1-4 and GPX6 being selenium-dependent
enzymes [43]. GPX1-3 enzymes can reduce H2 O2 as well as small organic hydroperoxides,
but GPX4 is uniquely able to reduce structurally complex phospholipid- and cholesterol
hydroperoxides [46]. Selenium (Se) is an essential trace element and dietary deficiency
of Se results in a marked loss of GPX activity in most tissues [47]. GPX1 is a major antioxidant enzyme found in the cytoplasm and mitochondria of most cells and in vitro
studies suggest this enzyme modulates redox-sensitive cellular responses by regulating
mitochondrial function [48]. Work by Chung et al. [49] has shown that GPX3 expression in
human skeletal muscle mediates the antioxidant effect of peroxisome proliferator-activated
receptor-gamma (PPAR-gamma). Moreover, these investigators also show that thiazo-
Antioxidants 2022, 11, 1336
5 of 17
lidinediones (TZDs), via their activation of PPAR-gamma, induce the expression of skeletal
muscle GPX3 and lower H2 O2 levels, which would otherwise cause insulin resistance (see
below). TZDs are medications that have been used in the management of T2D. Tissue
culture and animal model studies suggest that the GPX family of enzymes participate in
numerous regulatory phenomena, but their roles in diabetes and human health require
further research [43].
Figure 2. A model linking excess dietary fat to skeletal muscle mitochondrial emission of H2 O2 ,
insulin resistance, and the glutathione peroxides system. Excess dietary fat promotes electron leakage
•− radicals. Superoxide dismutase (SOD) converts
and the production of superoxide (O2 •− ) anion
•−
•−
O2 to H2 O2 , which is reduced by glutathione peroxidase (GPX) with the consumption of reduced
glutathione (GSH) and the formation of oxidized glutathione (GSSG). GSSG is recycled back to
GSH by glutathione reductase (GR) with the consumption of NADPH and the formation of NADP+ .
Glucose-6-phosphate dehydrogenase (G6PD), in turn, catalyzes the reduction of NADP+ to NADPH
utilizing glucose-6-phosphate (G-6P) provided by the action of hexokinase (HK) on glucose. Excess
H2 O2 emission into the skeletal muscle cytoplasm has been linked to insulin resistance (see text) and
a shift to reduced levels of GSH and increased levels of GSSG.
2.3. Mitochondrial H2 O2 Emission as a Potential Initiating Event for Insulin Resistance
There is considerable evidence linking mitochondrial oxidative stress and T2D [50].
Pioneering ex vivo, in vivo, in vitro, and dietary experiments by Anderson et al. [16]
show that a high-fat diet, either in rodents or humans, markedly increases skeletal muscle
mitochondrial H2 O2 emission, subsequently resulting in insulin resistance. Mitochondrial
H2 O2 arises from the superoxide dismutase (SOD) catalyzed conversion of the superoxide
radical (O2 •− ). The early development of insulin resistance in children is strongly associated
with obesity and the future development of T2D [51].
We will summarize the work of Anderson et al. in detail, given its etiological significance [16]. These researchers studied mitochondrial H2 O2 emission in isolated skeletal
muscle fibers. Mitochondrial H2 O2 emission was increased in skeletal muscle isolated from
normal Sprague-Dawley rats fed a high-fat diet compared (for 3 days or 3 weeks) to skeletal
muscle from rats fed a standard chow diet (high in carbohydrates). Notably, this effect was
Antioxidants 2022, 11, 1336
6 of 17
prevented by treating the high-fat diet rats with a mitochondrial-specific cell-permeable
synthetic antioxidant peptide (SS31). SS31 selectively localizes to the mitochondrial inner
membrane and is currently undergoing clinical trials [52]. As outlined in Figure 2, increased
emission of H2 O2 into the cytoplasm is expected to result in increased consumption of GSH
and formation of GSSG by GPX and a decreased cytosolic GSH/GSSG ratio. This expected
shift towards a more oxidized GSH state in the skeletal muscle of the rats fed the high-fat
diet was experimentally confirmed by Anderson et al. [16]. Moreover, treatment with SS31
prevented the high-fat diet-induced shift to a decreased GSH/GSSG ratio. Quite remarkably, the normal rats fed a high-fat diet for six weeks developed insulin resistance which
was completely blocked by treatment with SS31. Moreover, in rats fed the high-fat diet,
glucose ingestion did not result in the activation (by phosphorylation) of AKT (see above)
in skeletal muscle as was observed in rats fed the standard-high carbohydrate chow diet.
For rats fed the high-fat diet but treated with SS31, AKT phosphorylation was completely
restored [16]. Collectively, these data demonstrate that a high-fat diet induces insulin
resistance by modulating the AKT signaling pathway and thereby the plasma membrane
level of GLUT4.
To establish that increased mitochondrial H2 O2 emission was a primary factor causing
insulin resistance, these investigators studied transgenic mice overexpressing human catalase (CAT) in skeletal and cardiac mitochondria (MCAT mice). CAT is normally localized
to peroxisomes in most cells and is only found to be present in the mitochondria of rat
cardiac tissue [53]. Skeletal muscle mitochondrial H2 O2 emission in the MCAT mice fed a
high-fat diet was significantly below that in the control wild-type mice fed the high diet.
Most importantly, whole-body insulin sensitivity was preserved in the MCAT mice fed a
high-fat diet.
In their final series of ex vivo experiments, Anderson et al. [16] measured mitochondrial H2 O2 emission in human skeletal muscle biopsies from lean, insulin-sensitive males
and obese, insulin-resistance male subjects. The obese subjects showed a two- to four-fold
increase in mitochondrial H2 O2 emission and a marked decrease (at least 50%) in the
GSH/GSSG ratio. Moreover, four hours (the postprandial period) after feeding the lean
subjects a high-fat meal, their skeletal muscle mitochondrial H2 O2 emission increased
two- to four-fold, and their GSH/GSSG ratio decreased (at least 50%) compared to a 12-h
fasting state.
Collectively, these data strongly suggest that a high-fat diet is mechanistically linked
to skeletal muscle mitochondrial H2 O2 emission, altered cellular redox status, and the
development of insulin resistance. The authors suggest that while both carbohydrate and
fat ingestion cause increased mitochondrial H2 O2 emission, the effect of fat ingestion was
less transitory and still evident after a 12-h fast. These researchers did not look at plasma
POS in either their human or animal models. This would be useful in future studies since it
would help determine if plasma POS is produced secondarily by skeletal muscle oxidative
stress. Human experiments have shown that plasma oxidative markers increase after
acute exercise, suggesting that exercise-induced oxidative stress is not confined to cellular
compartments [54].
2.4. Hyperglycemia and Glycation Induced Oxidative Stress
While low insulin-stimulated transport of glucose into skeletal muscle is a key etiological factor in T2D, the resulting hyperglycemia is also a fundamental cause of pathophysiology. Hyperglycemia causes an increased glucose uptake in cells relying on insulinindependent GLUT transport, e.g., endothelial cells. Hyperglycemia or high intracellular
glucose (or fructose) promotes the non-enzymatic glycation of protein lysine (K) and arginine (R) residues as well as the N-terminal residue. This relatively stable glycation product
is termed an Amadori adduct that can further react to form AGEs [55]. The glycation level
of the N-terminal residue of hemoglobin (HbA1c) is a diagnostically useful measure of
long-term hyperglycemia in DM and for monitoring treatment efficacy. Glycation alters the
structure of Hb and its oxygen-binding functions in T2D [56]. Hb is not, however, a unique
Antioxidants 2022, 11, 1336
7 of 17
protein: any protein exposed to high glucose levels can be glycated at susceptible residues.
Since proteins are “nanomachines” performing most biological functions, their covalent
modification by glucose can be deleterious. K and R residues are at the active site of many
enzymes. In addition to proteins, lipids and nucleic acids can also be glycated [57].
The potential functional effects of glycation on proteins relevant to oxidative stress
in T2D are not well studied. The effects of glycation on selenium-dependent GPXs would
be particularly relevant given their potential etiological roles in T2D, as discussed above.
Plasma and RBC GPX activity are lower in T2D compared to healthy controls [58,59]. The
lower activity of GPX could be due to dietary selenium deficiency and glycation. The
selenium content of plasma GPX is, however, the same for T2D and normal subjects [59].
Moreover, in vitro glycation of GPX with glucose, fructose, or galactose results in loss of
GPX activity [59]. Although more research is warranted, these results strongly suggest that
glycation of GPXs negatively affects their enzymatic activity. This would be important in
GPXs in plasma as well as in the cytoplasm and mitochondria of cells where glucose uptake
is not insulin sensitive (e.g., RBCs and endothelial cells). Work by Goyal et al. also indicates
that RBC GPX activity level is more suppressed in obese T2D compared to non-obese T2D,
suggesting that obesity is a contributor to oxidative stress [58].
2.5. Advanced Glycation End Products (AGEs) and Oxidative Stress in T2D
The Amadori products resulting from protein glycation can undergo further covalent
modifications to form protein-AGEs [60]. As reviewed by Nowotny et al. [60], oxidative
stress is thought to promote the formation of protein-AGEs which, in turn, can act to
promote additional oxidative stress. The role of AGEs in promoting oxidative stress and in
the development of T2D is an area of active research [61]. AGEs bind to an AGE-specific
receptor (AGER or also termed RAGE) that, in turn, activates the transcription factor nuclear
factor NF-kappa-B (NFKB), which promotes the expression of inflammatory genes [62].
AGEs are thought to contribute to chronic oxidative stress in T2D and negatively impact
antioxidant systems [60]. Plasma proteins exposed to high levels of glycating sugars are,
therefore, subject to glycation and AGE formation. Albumin, the most abundant plasma
protein, forms site-specific AGE products that are high in patients with T2D and poor
glycemic control [63].
2.6. AGEs, Skeletal Muscle GLUT4 Expression, and Insulin Resistance
Interesting in vitro and in vivo work by Pinto-Junior et al. [62] in an animal model
indicates that albumin-AGE, in addition to being a biomarker for poor glycemic control,
could also induce insulin resistance by decreasing the expression of the GLUT4 gene (Scl2a4)
in skeletal muscle. In this work, normal rats treated with albumin-AGE for 12 weeks
developed insulin resistance as well as a decreased Scl2a4 mRNA expression and GLUT4
protein content. These data suggest that AGEs, independent of hyperglycemia, can affect
glucose uptake into skeletal muscle by decreasing the expression of GLUT4. This study
further suggests the possibility that repeated bouts of transient postprandial hyperglycemia
could gradually induce the formation of sufficient levels of albumin-AGE to induce a more
permanent long-term insulin resistance, as can be found in pre-diabetes. Rammos et al. [64]
reviewed the evidence linking chronic hyperglycemia-induced oxidative stress to T2D with
an emphasis on endothelial cell dysfunction.
2.7. Vascular Endothelial Cells, Oxidative Stress, and T2D
Vascular endothelial cells are in direct contact with the elevated plasma glucose levels
characteristically found in poorly controlled T2D. As stated by Kida et al. [65] “hyperglycemia is the primary cause of vascular complications occurring in individuals with
diabetes”. Endothelial cells primarily rely on GLUT1 (an insulin-independent transporter)
for glucose transport. In contrast to skeletal muscle cells, intracellular glucose levels in endothelial cells markedly increase in response to hyperglycemia and accumulate G-6P [66,67].
Endothelial cells utilize the polyol pathway to remove excess intracellular glucose [68,69].
Antioxidants 2022, 11, 1336
8 of 17
Under hyperglycemic conditions, about 30% of blood glucose moves through the
polyol pathway [69]. In this pathway (see Figure 3), glucose is first reduced to sorbitol
by aldose reductase and this reaction consumes NADPH. In the second step, sorbitol
is converted into fructose by sorbitol dehydrogenase and this reaction consumes NAD+
producing NADH. The net result of these two steps is the conversion of NADPH to
NADH and increased intracellular levels of fructose. Decreased intracellular NADPH
could result in a decreased ability of GR to reduce GSSG to GSH and thereby reduce the
ability of GPX to reduce H2 O2 or lipid hydroperoxides with a resulting increase in oxidative
stress [69,70]. Moreover, fructose is a reducing sugar and, like glucose, can glycate proteins,
alter their functions, and result in protein-AGEs. In vitro studies indicate that fructose
forms both glycation products and AGEs more effectively and rapidly than glucose [71].
Animal models also suggest that fructose promotes oxidative stress to a greater extent
than glucose [72]. Dietary AGEs are formed during high-temperature food processing,
as is typical for the Western diet [18]. Individuals with T2D show increased plasma POS,
and macro-and microvascular endothelial dysfunction, after consuming a meal rich in
AGEs [19].
Figure 3. The polyol pathway and oxidative stress. For cells in which hyperglycemia produces
high intracellular glucose levels, the polyol pathway is activated. Excess intracellular glucose is
converted to sorbitol by the action of aldose reductase (AR), which consumes NADPH. NADPH is
required to recycle oxidized glutathione (GSSG) to reduce glutathione (GSH) and reduce peroxides
(see Figure 1), which would otherwise cause oxidative stress. Sorbitol is converted to fructose by
sorbitol (SDH). Fructose is an effective glycating sugar-forming AGEs that promote oxidative stress
and inflammation.
3. System Medicine and a Future Redoxomics Approach to Pediatric T2D
Historically, medicine has largely utilized a reductionist approach in which disease
states are generally reduced to a single organ or defect. Consequently, this approach
often overlooks potential interactions between both intrinsic and extrinsic modulators and
environmental risk factors [73]. Alternatively, an integrative systems medicine approach
is becoming increasingly favored. Redoxomics is a branch of systems medicine focusing
on oxidative stress, reactive oxygen species, and antioxidants. Systems medicine, also
referred to as precision or “P4” medicine, captures the power of omics technologies, such
as genomics, epigenomics, proteomics, and metabolomics, and their interaction with
environmental factors like nutrition and the gut microbiome [74–78]. The goal of P4
medicine is to provide an integrated healthcare approach that is “predictive, preventive,
personalized and participatory” [79,80]. In short, systems medicine is interdisciplinary and
utilizes omic data to reveal pathophysiological processes useful for predicting the inherent
risk of an individual patient to developing a disease such as diabetes and to assess the
success likelihood of specific treatments [74–77].
As detailed above, considerable evidence supports the role of oxidative stress as an
initial etiological factor for pediatric T2D. It follows that redoxomics would be of optimal
clinical benefit while simultaneously providing detailed molecular insights into pathophysiology. A comprehensive application of redoxomics to either adult or youth-onset T2D
is currently lacking. An early childhood study with multiple follow-up periods would
be ideal since it might identify very early redoxomics biomarkers providing precision
Antioxidants 2022, 11, 1336
9 of 17
guidance for preventing or slowing future T2D development before irreversible pathology
occurs. We will next introduce the potential of a generalized systems medicine approach to
T2D and detail the ongoing contributions of omics technology to risk assessment, patient
stratification, and predicting drug responsiveness. We will also make a note of existing
omics data relevant to oxidative stress and T2D since this would help guide future redoxomic studies. These omics studies have mostly been limited to adults of Western European
origin, with some newer additions from East Asian populations [81–83]. Genomic technology is quite advanced, very comprehensive, cost-effective, and has overcome many
regulatory hurdles for providing data analysis reports directly to adult consumers.
3.1. Genomics and T2D
T2D has a strong genetic predisposition and published genome-wide association studies (GWAS) have identified over 500 single nucleotide polymorphisms (SNPs) associated
with susceptibility [81]. Nevertheless, these genetic variants have accounted for only about
10–20% of the heritability of T2D and some of these variants are also associated with obesity [83]. The relevant genetic risk factors can be combined into a polygenic T2D risk score
with the potential to inform healthcare decisions, e.g., the potential to respond to an oral
diabetic medication [84]. Very cost-effective commercial genotyping can currently provide
an estimate of T2D risk development for adults. The 23andme company provides a T2D
polygenic sore based on over 1000 genetic variants. About 20% of their research population
has a T2D genetic risk equal to that of being overweight. Nevertheless, 23andme did not
obtain Food and Drug Agency (FDA) clearance for the genetic risk score as it was characterized as a wellness product that does not make a diagnosis or provide medical advice. A
genetic risk score for youth onset T2D has not been published but could potentially provide
a sign to initiate early and robust lifestyle interventions.
3.1.1. Genomics and Stratification of Adult T2D Patients
A second major contribution of genomics to T2D lies in its potential to help categorize diabetes types and thereby provide more individualized healthcare. A controversial
Swedish study recently proposed that adult diabetes be subdivided into five groups rather
than the current two [85]. Six measures were utilized to assign a patient to a group: body
BMI, age at diabetes diagnosis, HbA1C level, beta-cell functionality, insulin resistance, and
the presence of diabetes-related autoantibodies. Significantly, the five types of DM categorized by these parameters were genetically distinct. These are very promising results and
extending these studies to additional ethnic populations as well as the pediatric population
could have enormous healthcare-related significance.
3.1.2. Genomics May Help Stratify Youth Onset T2D Patients
The possibility of using genomics to help stratify youth onset T2D is a high-priority
future goal. In a consensus report, Nadeau et al. [86] reviewed the clinical evidence
suggesting that youth-onset T2D is unique and distinct from T2D in adults. Youth-onset
T2D is characterized by both a rapid beta-cell decline and an accelerated progression.
The underlying pathophysiological mechanisms for these unique alterations are not well
understood. The consensus report asserts that new and comprehensive strategies for
treating youth-onset T2D “are urgently needed” [86]. A systems medicine approach will
most likely contribute to future efforts at developing targeted treatments.
3.1.3. Genomics and Oxidative Stress
GWAS studies on oxidative stress in humans are still “a work in progress,” although
studies in other organisms have provided a useful framework [87]. Variants in CAT, GPX4,
and GSR (glutathione reductase) and the transcription factor nuclear factor-erythroid factor
2-related factor 2 (Nrf2) have been found to modulate human oxidative stress [88]. Despite
their potential importance, biomarkers for oxidative stress in T2D are not clinically used to
categorize DM or guide healthcare. Tabatabaei-Malazy et al. have reviewed the potential
Antioxidants 2022, 11, 1336
10 of 17
relevance of polymorphisms in antioxidant genes to T2D or its clinical complications [89].
These authors stress the need for additional studies focusing on epigenetic mechanisms
regulating the expression of antioxidant enzymes. Future GWAS studies in the pediatric
population could benefit from looking at the genetic variants contributing to POS, the
development of pediatric insulin resistance, prediabetes, and T2D. Given the potential
importance of mitochondria in T2D, it may prove useful to place more emphasis on
mitochondrial DNA variants, as suggested by Wang et al. [90]. Mitochondrial DNA is
particularly susceptible to oxidative stress-induced mutations and DNA damage [90].
Circulating mitochondrial DNA, thought to arise from stressed cells, may be a non-invasive
biomarker for T2D [91].
3.2. Metabolomics, Oxidative Stress, and T2D
The potential clinical applications of metabolomics to oxidative stress-induced alterations in cytosolic, mitochondrial, and redox metabolites hold great promise [92]. It has
been well documented, for example, that branched-chain amino acids (BCAAs) are elevated
in T2D [93]. BCAAs include leucine, isoleucine and valine. In vitro and ex vivo experiments
demonstrate that BCAAs promote endothelial dysfunction via increased mitochondrial
ROS generation and increased formation of peroxynitrite and 3-nitro-tyrosine [94]. The
induction of oxidative stress in endothelial cells is thought to be caused by activation of the
mTORC1 pathway [94]. GWAS/metabolomic studies have confirmed a causal role between
the level of insulin resistance and levels of circulating BCAAs [95].
In 2011, Wang et al. utilized a targeted metabolomic approach to evaluate the risk
of developing T2D in adults [96]. In this study, a metabolic profile (over 60 metabolites)
was measured in the fasting plasma of 2422 healthy, non-diabetic subjects. After a 12-year
follow-up period, 201 individuals developed T2D. Quite significantly, plasma BCAAs
levels (and that of two aromatic amino acids) had a significant association with future T2D
development that was superior to BMI, dietary pattern, and fasting glucose [96].
Lipidomics is a subset of metabolomics looking only at lipid metabolites in a given
biofluid/biosample. When fasting plasma is used, the lipids sampled will primarily
represent lipids associated with lipoproteins and not cellular biomembranes. Recent
research in a Swedish population shows that a “lipidomic risk,” based on a single mass
spectrometric measurement in a plasma sample, can identify a subset of adult individuals
at high risk for developing T2D. Moreover, the lipidomic risk score was largely independent
of the polygenic risk score [97].
3.3. Proteomics and T2D
Chen and Gerszten have reviewed the potential of proteomics for advancing T2D
healthcare [98]. These authors suggest that integrating circulating metabolomics and
proteomics (i.e., multiomics) would be an optimum strategy. For large-scale population
studies and future pediatric studies, the emphasis on plasma is realistic. As postulated
above, skeletal muscle mitochondrial alterations are likely to be of etiological significance
for T2D, and plasma (or RBC) would not be as mechanistically informative as a skeletal
muscle biopsy. Future mechanistic multiomic studies with skeletal muscle biopsies remain
critical for advancing an in-depth understanding of T2D. For children, skeletal muscle
biopsies are bioethically justified only with specific medical justification. Following tissue
damage, tissue-specific proteins can leak into plasma but are usually present only in low
abundance making their detection and quantification technologically challenging (more on
this below).
3.3.1. Protein Glycation and Oxidation in T2D
Plasma and RBC samples can provide quantitative information on proteins that have
been modified by glycation, AGE formation, or oxidative stress. A comprehensive list
of glycated proteins from the plasma and RBCs of control and T2D subjects has been
published, with several proteins being significantly more glycated in T2D subjects [55].
Antioxidants 2022, 11, 1336
11 of 17
Interestingly, GPX3 (plasma glutathione peroxidase) was found to be glycated at four
distinct peptide sequences. Carbonylated plasma proteins can be formed directly from ROS
modifications of susceptible amino acid residues or by the covalent addition of adducts
with carbonyl groups as they arise from glycation [99,100]. Carbonylated proteins are not,
therefore, a good measure of ROS-mediated protein oxidation alone. Although lacking
quantification, Bollineni et al. [100] looked at the presence of carbonylated plasma proteins
in a small population of lean subjects and obese subjects with or without T2D. A unique
set of carbonylated proteins were found only in the obese T2D subjects. These unique
proteins need to be confirmed by additional studies (including pediatric subjects) but
strongly suggest that carbonylated plasma proteins could provide biomarkers for obesityinduced T2D.
3.3.2. The Proximity Ligation Assay, T2D, and Metformin Response Stratification
Traditional proteomics utilizing highly specialized modern spectrometry equipment
is well suited for basic research, exploratory clinical research, and proteome discovery.
Fu et al. [101] have detailed the potential power of label-free quantitation for biomarker
discovery in diabetes. The utility of the proximity ligation assay (PIA) for T2D precision
medicine and biomarker discovery has recently been demonstrated in a modest cohort of
healthy and T2D subjects [102].
PIA can be used for the detection of proteins, post-translational modifications (e.g.,
glycation) and protein-protein interactions [103,104]. In this assay, two complementary
DNA-tagged antibodies bind to epitopes in close proximity to each other on the same target
protein. DNA in the matched pair of tagged antibodies hybridize, is extended by DNA
polymerase, and amplified by the quantitative polymerase chain reaction (qPCR) or nextgeneration sequencing (NGS). The amplified DNA is essentially a unique double-stranded
“barcode” for a specific target protein and the number of readouts of that unique barcode
is a quantitative measure of the target protein’s level in the sample. This assay can be
multiplexed to quantify many proteins in a given sample.
Utilizing microliter amounts of fasting plasma, Zhong et al. could quantify about
1500 proteins (with NGS readout) in an adult Swedish population, including low abundance proteins [102]. They found that the plasma proteome significantly varied from one
healthy individual to the next, but each had a unique profile that was stable over time.
Two populations of T2D subjects were studied, i.e., obese and non-obese. Four proteins
were found to have significantly altered expression between these two groups (one was
leptin). They then examined the protein profiles of non-obese T2D patients with non-obese
healthy patients and found 32 proteins with altered expression. The authors suggest these
32 proteins might serve to identify subjects at increased T2D risk despite not being obese.
They next attempted to stratify T2D patients based on their responses to metformin treatment. A total of 40 T2D subjects were treated with metformin for three months and these
were stratified into responders, non-responders, and an intermediate group. Significantly,
30 proteins in the plasma proteome measured at baseline (before the start of metformin intervention) could distinguish the responders from the non-responders. This result suggests
that the panel of 30 proteins could be used to predict whether a Swedish adult T2D patient
would respond well to metformin therapy.
In contrast to the overall positive responses of T2D adults to metformin alone or
insulin treatment followed by metformin, youth-onset T2D shows no improvement in
progressive beta-cell deterioration [105]. This again points to the uniqueness of youth-onset
T2D and the speculation that redoxomics could help define relevant factors for preserving
beta-cell function and preventing T2D progression.
Once a subset of proteins has been established to have clinical relevance, proteomics
can shift from a discovery mode to a targeted mode in which only this subset is quantified.
To be of practical use in systems medicine, targeted proteomic analyses need to be highly
sensitive and specific with high throughput and long-term reproducibility. The PEA assay
Antioxidants 2022, 11, 1336
12 of 17
is very promising in this regard and could easily be expanded to look at relevant plasmaproteins covalently modified by glycation, AGE formation, and oxidative stress.
4. System Medicine, Nutrigenomics and T2D
As detailed above, obesity, excess dietary calories, lack of exercise, and poor diet all
contribute to T2D risk and progression (see Figure 1). Interventions aimed at correcting
these lifestyle issues are central to individual care and relevant public health policies and
programs. The American Diabetes Association supports “evidence-based nutrition standards for school meals and snacks, and other child nutrition programs” [106]. In addition to
total calories, fat levels and type, fiber content, and glycemic index, it would also be useful
to consider the levels of various dietary antioxidants and dietary AGEs [107]. Nutrients and
dietary patterns are also known to influence gene expression in ways potentially relevant
to the causes and development of T2D [108].
Nutrigenomics is emerging as an area possibly important in T2D prevention and
treatment [109]. Nutrigenomics is a branch of systems medicine studying the interactions
between genes and nutrients [110]. Many polyphenols, in addition to having intrinsic
antioxidant properties, are also bioactive compounds that can potentially alter the expression of genes important to T2D [109]. Resveratrol, quercetin, genistein, catechins,
and curcumin are bioactive dietary polyphenols that may play a role in T2D prevention/management [109,111,112]. Both GSH and ascorbate are water-soluble antioxidants
that may also play protective roles in T2D. Dietary ascorbate supplementation may improve
glycemic control, but further clinical trials are necessary [113]. Similarly, a short-term pilot
study with glycine and N-acetylcysteine supplementation (precursors of GSH) improves
mitochondrial dysfunction and insulin resistance in adult T2D patients [114,115].
5. Conclusions
Adopting a systems medicine approach to T2D may require significant clinical and educational changes. Some medical schools, like Georgetown University, already implement
systems medicine into their curriculum [75,116]. It is important to note that much of the
preliminary research into the systems medicine of diabetes has been done with adult populations of mostly Western European descent. There is a critical need to extend these studies
to pediatric populations and ethnically diverse populations. Youth onset T2D may prove to
have a genetic risk score with a unique set of gene variants compared to adult-onset T2D.
As detailed above, dietary-induced oxidative stress (see Figure 1) is likely an early initiating
event for T2D progression and, therefore, of etiological significance to pediatric T2D. The
comprehensive characterization of redox status provided by redoxomics holds great future
promise in helping to evaluate the efficacy of lifestyle and nutritional interventions for
T2D as well as the application of precision medicine. A multiomics approach that would
utilize a targeted panel of genomic, metabolomic, and proteomic biomarkers is likely to
be optimal.
Author Contributions: Conceptualization, S.N.A., E.A.L. and W.L.S.; writing—original draft preparation, S.N.A., E.A.L., G.A.F. and W.L.S.; writing—review and editing, S.N.A., E.A.L., G.A.F. and
W.L.S.; funding acquisition, W.L.S. and East Tennessee State University. All authors have read and
agreed to the published version of the manuscript.
Funding: This research was supported in part by the National Institutes of Health grant C06RR0306551
and the East Tennessee State University Robert W. Summers Pediatric Research Endowment.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
Yang, W.; Dall, T. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018, 41, 917–928. [CrossRef]
CDC. Type 2 Diabetes. Available online: https://www.cdc.gov/diabetes/basics/type2.html (accessed on 9 February 2022).
Antioxidants 2022, 11, 1336
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
13 of 17
Mayer-Davis, E.J.; Kahkoska, A.R.; Jefferies, C.; Dabelea, D.; Balde, N.; Gong, C.X.; Aschner, P.; Craig, M.E. ISPAD Clinical Practice
Consensus Guidelines 2018: Definition, Epidemiology, and Classification of Diabetes in Children and Adolescents. Pediatric
Diabetes 2018, 19 (Suppl. 27), 7–19. [CrossRef] [PubMed]
Pulgaron, E.R.; Delamater, A.M. Obesity and Type 2 Diabetes in Children: Epidemiology and Treatment. Curr. Diabetes Rep. 2014,
14, 508. [CrossRef] [PubMed]
Andes, L.J.; Cheng, Y.J.; Rolka, D.B.; Gregg, E.W.; Imperatore, G. Prevalence of Prediabetes Among Adolescents and Young
Adults in the United States, 2005–2016. JAMA Pediatric 2020, 174, e194498. [CrossRef] [PubMed]
1 in 5 Adolescents and 1 in 4 Young Adults Now Living with Prediabete. Available online: https://www.cdc.gov/media/
releases/2019/p1202-diabetes.html (accessed on 2 May 2022).
Imperatore, G.; Boyle, J.P.; Thompson, T.J.; Case, D.; Dabelea, D.; Hamman, R.F.; Lawrence, J.M.; Liese, A.D.; Liu, L.L.; MayerDavis, E.J.; et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: Dynamic
modeling of incidence, mortality, and population growth. Diabetes Care 2012, 35, 2515–2520. [CrossRef]
Garber, A.J.; Abrahamson, M.J.; Barzilay, J.I.; Blonde, L.; Bloomgarden, Z.T.; Bush, M.A.; Dagogo-Jack, S.; DeFronzo, R.A.; Einhorn,
D.; Fonseca, V.A.; et al. Consensus statement by the american association of clinical endocrinologists and american college of
endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr. Pract. 2018, 24,
91–120. [CrossRef]
Mechanick, J.I.; Garber, A.J.; Grunberger, G.; Handelsman, Y.; Garvey, W.T. Dysglycemia-based chronic disease: An american
association of clinical endocrinologists position statement. Endocr. Pract. 2018, 24, 995–1011. [CrossRef]
Green, K.; Brand, M.D.; Murphy, M.P. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes.
Diabetes 2004, 53 (Suppl. 1), S110–S118. [CrossRef]
Tafuri, S.; Cocchia, N.; Landolfi, F.; Ciani, F.; Iorio, E.L. Redoxomics and Oxidative Stress: From the Basic Research to the Clinical
Practice. Free Rad. Dis. 2016, 149–169. [CrossRef]
Dansinger, M. Type 2 Diabetes in Children. 2021. Available online: www.webmd.com/diabetes/type-2-diabetes-in-children
(accessed on 2 May 2022).
Frohnert, B.I.; Jacobs, D.R.; Steinberger, J.; Moran, A.; Steffen, L.M.; Sinaiko, A.R. Relation between serum free fatty acids
and adiposity, insulin resistance, and cardiovascular risk factors from adolescence to adulthood. Diabetes 2013, 62, 3163–3169.
[CrossRef]
Wright, E.; Scism-Bacon, J.L.; Glass, L.C. Oxidative stress in type 2 diabetes: The role of fasting and postprandial glycaemia. Int. J.
Clin. Pract. 2006, 60, 308–314. [CrossRef] [PubMed]
Sottero, B.; Gargiulo, S.; Russo, I.; Barale, C.; Poli, G.; Cavalot, F. Postprandial Dysmetabolism and Oxidative Stress in Type 2
Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Med. Res. Rev. 2015, 35, 968–1031. [CrossRef] [PubMed]
Anderson, E.J.; Lustig, M.E.; Boyle, K.E.; Woodlief, T.L.; Kane, D.A.; Lin, C.T.; Price, J.W.; Kang, L.; Rabinovitch, P.S.; Szeto,
H.H.; et al. Mitochondrial H2 O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and
humans. J. Clin. Investig. 2009, 119, 573–581. [CrossRef] [PubMed]
Neri, S.; Calvagno, S.; Mauceri, B.; Misseri, M.; Tsami, A.; Vecchio, C.; Mastrosimone, G.; Di Pino, A.; Maiorca, D.; Judica, A.; et al.
Effects of antioxidants on postprandial oxidative stress and endothelial dysfunction in subjects with impaired glucose tolerance
and type 2 diabetes. Eur. J. Nutr. 2010, 49, 409–416. [CrossRef]
Ottum, M.S.; Mistry, A.M. Advanced glycation end-products: Modifiable environmental factors profoundly mediate insulin
resistance. J. Clin. Biochem. Nutr. 2015, 57, 1–12. [CrossRef]
Stirban, A.; Negrean, M.; Stratmann, B.; Gawlowski, T.; Horstmann, T.; Götting, C.; Kleesiek, K.; Mueller-Roesel, M.; Koschinsky,
T.; Uribarri, J.; et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a
meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006, 29, 2064–2071. [CrossRef]
Bloomer, R.J.; Kabir, M.M.; Marshall, K.E.; Canale, R.E.; Farney, T.M. Postprandial oxidative stress in response to dextrose and
lipid meals of differing size. Lipids Health Dis. 2010, 9, 79. [CrossRef]
Perez-Martinez, P.; Garcia-Quintana, J.M.; Yubero-Serrano, E.M.; Tasset-Cuevas, I.; Tunez, I.; Garcia-Rios, A.; Delgado-Lista, J.;
Marin, C.; Perez-Jimenez, F.; Roche, H.M.; et al. Postprandial oxidative stress is modified by dietary fat: Evidence from a human
intervention study. Clin. Sci. 2010, 119, 251–261. [CrossRef]
Yubero-Serrano, E.M.; Garcia-Rios, A.; Delgado-Lista, J.; Delgado-Casado, N.; Perez-Martinez, P.; Rodriguez-Cantalejo, F.; Fuentes,
F.; Cruz-Teno, C.; Tunez, I.; Tasset-Cuevas, I.; et al. Postprandial effects of the Mediterranean diet on oxidant and antioxidant
status in elderly men and women. J. Am. Geriatr. Soc. 2011, 59, 938–940. [CrossRef]
Forouhi, N.G.; Misra, A.; Mohan, V.; Taylor, R.; Yancy, W. Dietary and nutritional approaches for prevention and management of
type 2 diabetes. BMJ 2018, 361, k2234. [CrossRef]
Georgoulis, M.; Kontogianni, M.D.; Yiannakouris, N. Mediterranean Diet and Diabetes: Prevention and Treatment. Nutrients
2014, 6, 1406–1423. [CrossRef] [PubMed]
Billingsley, H.E.; Carbone, S. The antioxidant potential of the Mediterranean diet in patients at high cardiovascular risk: An
in-depth review of the PREDIMED. Nutr. Diabetes 2018, 8, 13. [CrossRef]
Velázquez-López, L.; Santiago-Díaz, G.; Nava-Hernández, J.; Muñoz-Torres, A.V.; Medina-Bravo, P.; Torres-Tamayo, M.
Mediterranean-style diet reduces metabolic syndrome components in obese children and adolescents with obesity. BMC
Pediatrics 2014, 14, 175. [CrossRef] [PubMed]
Antioxidants 2022, 11, 1336
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
14 of 17
Stone, W.L.; Pham, T.; Mohiuddin, S.S. Biochemistry, Antioxidants. In StatPearls; 2020. Available online: https://www.ncbi.nlm.
nih.gov/books/NBK541064/ (accessed on 2 May 2022).
Rajan, A.S. Regulation of Glucose Uptake. Available online: https://www.medscape.org/viewarticle/438374 (accessed on
2 May 2022).
Quijano, C.; Trujillo, M.; Castro, L.; Trostchansky, A. Interplay between oxidant species and energy metabolism. Redox Biol. 2016,
8, 28–42. [CrossRef]
Barrett, E.J.; Liu, Z. The endothelial cell: An “early responder” in the development of insulin resistance. Rev. Endocr. Metab.
Disord. 2013, 14, 21–27. [CrossRef] [PubMed]
Ciaraldi, T.P.; Mudaliar, S.; Barzin, A.; Macievic, J.A.; Edelman, S.V.; Park, K.S.; Henry, R.R. Skeletal muscle GLUT1 transporter
protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J. Clin. Endocrinol. Metab. 2005, 90, 352–358.
[CrossRef] [PubMed]
Richter, E.A.; Hargreaves, M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol. Rev. 2013, 93, 993–1017. [CrossRef]
Huang, X.; Liu, G.; Guo, J.; Su, Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int. J. Biol. Sci. 2018, 14, 1483–1496.
[CrossRef]
DeFronzo, R.A.; Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32
(Suppl. 2), S157–S163. [CrossRef]
Lebovitz, H.E. Insulin resistance: Definition and consequences. Exp. Clin. Endocrinol. Diabetes 2001, 109 (Suppl. 2), S135–S148.
[CrossRef]
Hudish, L.I.; Reusch, J.E.; Sussel, L. β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J. Clin.
Investig. 2019, 129, 4001–4008. [CrossRef] [PubMed]
İhsan, B.; Türkan, Y.; Handan, A. Is Oxidative Stress a Consequence of Hyperglycemia? Or is Hyperglycemia the Consequence of
Oxidative Stress? Or are Both Caused by Insulin Resistance? Int. Arch. Endocrinol. Clin. Res. 2021, 7, 023. [CrossRef]
Kyselová, P.; Zourek, M.; Rusavý, Z.; Trefil, L.; Racek, J. Hyperinsulinemia and oxidative stress. Physiol. Res. 2002, 51, 591–595.
[PubMed]
Cline, G.W.; Petersen, K.F.; Krssak, M.; Shen, J.; Hundal, R.S.; Trajanoski, Z.; Inzucchi, S.; Dresner, A.; Rothman, D.L.; Shulman,
G.I. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N. Engl.
J. Med. 1999, 341, 240–246. [CrossRef] [PubMed]
Rothman, D.L.; Shulman, R.G.; Shulman, G.I. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate.
Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes
mellitus. J. Clin. Investig. 1992, 89, 1069–1075. [CrossRef]
Yang, H.C.; Wu, Y.H.; Yen, W.C.; Liu, H.Y.; Hwang, T.L.; Stern, A.; Chiu, D.T. The Redox Role of G6PD in Cell Growth, Cell Death,
and Cancer. Cells 2019, 8, 1055. [CrossRef]
Ge, T.; Yang, J.; Zhou, S.; Wang, Y.; Li, Y.; Tong, X. The Role of the Pentose Phosphate Pathway in Diabetes and Cancer. Front.
Endocrinol. 2020, 11, 365. [CrossRef]
Brigelius-Flohé, R.; Flohé, L. Regulatory Phenomena in the Glutathione Peroxidase Superfamily. Antioxid. Redox Signal. 2020, 33,
498–516. [CrossRef]
Mahmoud, A.A.; Nor El-Din, A.K. Glucose-6-Phosphate Dehydrogenase Activity and Protein Oxidative Modification in Patients
with Type 2 Diabetes Mellitus. J. Biomark. 2013, 2013, 430813. [CrossRef]
Heymann, A.D.; Cohen, Y.; Chodick, G. Glucose-6-phosphate dehydrogenase deficiency and type 2 diabetes. Diabetes Care 2012,
35, e58. [CrossRef]
Weaver, K.; Skouta, R. The Selenoprotein Glutathione Peroxidase 4: From Molecular Mechanisms to Novel Therapeutic Opportunities. Biomedicines 2022, 10, 891. [CrossRef] [PubMed]
Stone, W.; Dratz, E. Selenium and non-selenium glutathione peroxidase activities in selected ocular and non-ocular rat tissues.
Exp. Eye Res. 1982, 35, 405–412. [CrossRef]
Handy, D.E.; Lubos, E.; Yang, Y.; Galbraith, J.D.; Kelly, N.; Zhang, Y.Y.; Leopold, J.A.; Loscalzo, J. Glutathione peroxidase1 regulates mitochondrial function to modulate redox-dependent cellular responses. J. Biol. Chem. 2009, 284, 11913–11921.
[CrossRef]
Chung, S.S.; Kim, M.; Youn, B.S.; Lee, N.S.; Park, J.W.; Lee, I.K.; Lee, Y.S.; Kim, J.B.; Cho, Y.M.; Lee, H.K.; et al. Glutathione
peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
Mol. Cell. Biol. 2009, 29, 20–30. [CrossRef] [PubMed]
Victor, V.M.; Rocha, M.; Herance, R.; Hernandez-Mijares, A. Oxidative stress and mitochondrial dysfunction in type 2 diabetes.
Curr. Pharm. Des. 2011, 17, 3947–3958. [CrossRef]
Tagi, V.M.; Giannini, C.; Chiarelli, F. Insulin Resistance in Children. Front. Endocrinol. 2019, 10, 342. [CrossRef] [PubMed]
Chavez, J.D.; Tang, X.; Campbell, M.D.; Reyes, G.; Kramer, P.A.; Stuppard, R.; Keller, A.; Zhang, H.; Rabinovitch, P.S.; Marcinek,
D.J.; et al. Mitochondrial protein interaction landscape of SS-31. Proc. Natl. Acad. Sci. USA 2020, 117, 15363–15373. [CrossRef]
Bai, J.; Cederbaum, A.I. Mitochondrial catalase and oxidative injury. Biol. Signals Recept. 2001, 10, 189–199. [CrossRef]
Quindry, J.; Stone, W.; King, J.; Broeder, C. The effects of acute exercise on neutrophils and plasma oxidative stress. Med. Sci.
Sports Exerc. 2003, 35, 1139–1145. [CrossRef]
Antioxidants 2022, 11, 1336
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
15 of 17
Zhang, Q.; Monroe, M.E.; Schepmoes, A.A.; Clauss, T.R.; Gritsenko, M.A.; Meng, D.; Petyuk, V.A.; Smith, R.D.; Metz, T.O.
Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic
subjects. J. Proteome Res. 2011, 10, 3076–3088. [CrossRef]
Pu, L.J.; Shen, Y.; Lu, L.; Zhang, R.Y.; Zhang, Q.; Shen, W.F. Increased blood glycohemoglobin A1c levels lead to overestimation
of arterial oxygen saturation by pulse oximetry in patients with type 2 diabetes. Cardiovasc. Diabetol. 2012, 11, 110. [CrossRef]
[PubMed]
Indyk, D.; Bronowicka-Szydełko, A.; Gamian, A.; Kuzan, A. Advanced glycation end products and their receptors in serum of
patients with type 2 diabetes. Sci. Rep. 2021, 11, 13264. [CrossRef] [PubMed]
Goyal, R.; Singhai, M.; Faizy, A.F. Glutathione peroxidase activity in obese and nonobese diabetic patients and role of hyperglycemia in oxidative stress. J. Midlife Health 2011, 2, 72–76. [CrossRef] [PubMed]
González de Vega, R.; Fernández-Sánchez, M.L.; Fernández, J.C.; Álvarez Menéndez, F.V.; Sanz-Medel, A. Selenium levels and
Glutathione peroxidase activity in the plasma of patients with type II diabetes mellitus. J. Trace Elem. Med. Biol. 2016, 37, 44–49.
[CrossRef]
Nowotny, K.; Jung, T.; Höhn, A.; Weber, D.; Grune, T. Advanced glycation end products and oxidative stress in type 2 diabetes
mellitus. Biomolecules 2015, 5, 194–222. [CrossRef]
Salazar, J.; Navarro, C.; Ortega, Á.; Nava, M.; Morillo, D.; Torres, W.; Hernández, M.; Cabrera, M.; Angarita, L.; Ortiz, R.; et al.
Advanced Glycation End Products: New Clinical and Molecular Perspectives. Int. J. Environ. Res. Public Health 2021, 18, 7236.
[CrossRef]
Pinto-Junior, D.C.; Silva, K.S.; Michalani, M.L.; Yonamine, C.Y.; Esteves, J.V.; Fabre, N.T.; Thieme, K.; Catanozi, S.; Okamoto, M.M.;
Seraphim, P.M.; et al. Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4
expression. Sci. Rep. 2018, 8, 8109. [CrossRef]
Greifenhagen, U.; Frolov, A.; Blüher, M.; Hoffmann, R. Plasma Proteins Modified by Advanced Glycation End Products (AGEs)
Reveal Site-specific Susceptibilities to Glycemic Control in Patients with Type 2 Diabetes. J. Biol. Chem. 2016, 291, 9610–9616.
[CrossRef]
Rammos, G.; Peppes, V.; Zakopoulos, N. Transient insulin resistance in normal subjects: Acute hyperglycemia inhibits endothelialdependent vasodilatation in normal subjects. Metab. Syndr. Relat. Disord. 2008, 6, 159–170. [CrossRef]
Kida, T.; Oku, H.; Osuka, S.; Horie, T.; Ikeda, T. Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by
the mTOR inhibitor, rapamycin. Sci. Rep. 2021, 11, 1885. [CrossRef]
Bakker, W.; Eringa, E.C.; Sipkema, P.; van Hinsbergh, V.W. Endothelial dysfunction and diabetes: Roles of hyperglycemia,
impaired insulin signaling and obesity. Cell Tissue Res. 2009, 335, 165–189. [CrossRef] [PubMed]
Sweet, I.R.; Gilbert, M.; Maloney, E.; Hockenbery, D.M.; Schwartz, M.W.; Kim, F. Endothelial inflammation induced by excess
glucose is associated with cytosolic glucose 6-phosphate but not increased mitochondrial respiration. Diabetologia 2009, 52,
921–931. [CrossRef] [PubMed]
Gero, D. Hyperglycemia-Induced Endothelial Dysfunction. In Endothelial Dysfunction—Old Concepts and New Challenges; IntechOpen: London, UK, 2007; pp. 179–206. [CrossRef]
Yan, L.J. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Anim. Model. Exp. Med. 2018, 1, 7–13. [CrossRef]
[PubMed]
Flohé, L.; Brand, I. Kinetics of glutathione peroxidase. Biochim. Biophys. Acta 1969, 191, 541–549. [CrossRef]
Aragno, M.; Mastrocola, R. Dietary Sugars and Endogenous Formation of Advanced Glycation Endproducts: Emerging Mechanisms of Disease. Nutrients 2017, 9, 385. [CrossRef]
Levi, B.; Werman, M.J. Long-term fructose consumption accelerates glycation and several age-related variables in male rats.
J. Nutr. 1998, 128, 1442–1449. [CrossRef]
Fiandaca, M.S.; Mapstone, M.; Connors, E.; Jacobson, M.; Monuki, E.S.; Malik, S.; Macciardi, F.; Federoff, H.J. Systems healthcare:
A holistic paradigm for tomorrow. BMC Syst. Biol. 2017, 11, 142. [CrossRef]
Kussmann, M.; Morine, M.J.; Hager, J.; Sonderegger, B.; Kaput, J. Perspective: A systems approach to diabetes research. Front.
Genet. 2013, 4, 205. [CrossRef]
Gustafsson, M.; Nestor, C.E.; Zhang, H.; Barabási, A.L.; Baranzini, S.; Brunak, S.; Chung, K.F.; Federoff, H.J.; Gavin, A.C.; Meehan,
R.R.; et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med. 2014, 6, 82.
[CrossRef]
Mardinoglu, A.; Nielsen, J. Systems medicine and metabolic modelling. J. Intern. Med. 2012, 271, 142–154. [CrossRef]
Olivier, M.; Asmis, R.; Hawkins, G.A.; Howard, T.D.; Cox, L.A. The Need for Multi-Omics Biomarker Signatures in Precision
Medicine. Int. J. Mol. Sci. 2019, 20, 4781. [CrossRef] [PubMed]
Apweiler, R.; Beissbarth, T.; Berthold, M.R.; Blüthgen, N.; Burmeister, Y.; Dammann, O.; Deutsch, A.; Feuerhake, F.; Franke, A.;
Hasenauer, J.; et al. Whither systems medicine? Exp. Mol. Med. 2018, 50, e453. [CrossRef] [PubMed]
Flores, M.; Glusman, G.; Brogaard, K.; Price, N.D.; Hood, L. P4 medicine: How systems medicine will transform the healthcare
sector and society. Pers. Med. 2013, 10, 565–576. [CrossRef] [PubMed]
Hood, L.; Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive,
personalized and participatory. New Biotechnol. 2012, 29, 613–624. [CrossRef]
Antioxidants 2022, 11, 1336
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
16 of 17
Liu, Y.; Wang, Y.; Qin, S.; Jin, X.; Jin, L.; Gu, W.; Mu, Y. Insights Into Genome-Wide Association Study for Diabetes: A Bibliometric
and Visual Analysis From 2001 to 2021. Front. Endocrinol. 2022, 13, 817620. [CrossRef]
Polfus, L.M.; Darst, B.F.; Highland, H.; Sheng, X.; Ng, M.C.Y.; Below, J.E.; Petty, L.; Bien, S.; Sim, X.; Wang, W.; et al. Genetic
discovery and risk characterization in type 2 diabetes across diverse populations. HGG Adv. 2021, 2, 100029. [CrossRef]
Xue, A.; Wu, Y.; Zhu, Z.; Zhang, F.; Kemper, K.E.; Zheng, Z.; Yengo, L.; Lloyd-Jones, L.R.; Sidorenko, J.; McRae, A.F.; et al.
Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat.
Commun. 2018, 9, 2941. [CrossRef]
Udler, M.S.; McCarthy, M.I.; Florez, J.C.; Mahajan, A. Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine. Endocr.
Rev. 2019, 40, 1500–1520. [CrossRef]
Ahlqvist, E.; Storm, P.; Käräjämäki, A.; Martinell, M.; Dorkhan, M.; Carlsson, A.; Vikman, P.; Prasad, R.B.; Aly, D.M.; Almgren,
P.; et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six
variables. Lancet Diabetes Endocrinol. 2018, 6, 361–369. [CrossRef]
Nadeau, K.J.; Anderson, B.J.; Berg, E.G.; Chiang, J.L.; Chou, H.; Copeland, K.C.; Hannon, T.S.; Huang, T.T.; Lynch, J.L.; Powell,
J.; et al. Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. Diabetes Care 2016, 39,
1635–1642. [CrossRef]
Weber, A.L.; Khan, G.F.; Magwire, M.M.; Tabor, C.L.; Mackay, T.F.; Anholt, R.R. Genome-wide association analysis of oxidative
stress resistance in Drosophila melanogaster. PLoS ONE 2012, 7, e34745. [CrossRef] [PubMed]
Zhan, M.; Wang, H.; Xu, S.W.; Yang, L.H.; Chen, W.; Zhao, S.X.; Shen, H.; Liu, Q.; Yang, R.M.; Wang, J. Variants in oxidative
stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer. EBioMedicine
2019, 48, 143–160. [CrossRef] [PubMed]
Tabatabaei-Malazy, O.; Khodaeian, M.; Bitarafan, F.; Larijani, B.; Amoli, M.M. Polymorphisms of Antioxidant Genes as a Target
for Diabetes Management. Int. J. Mol. Cell Med. 2017, 6, 135–147. [CrossRef] [PubMed]
Wang, P.W.; Lin, T.K.; Weng, S.W.; Liou, C.W. Mitochondrial DNA variants in the pathogenesis of type 2 diabetes—Relevance of
asian population studies. Rev. Diabetes Stud. 2009, 6, 237–246. [CrossRef] [PubMed]
Silzer, T.; Barber, R.; Sun, J.; Pathak, G.; Johnson, L.; O’Bryant, S.; Phillips, N. Circulating mitochondrial DNA: New indices of
type 2 diabetes-related cognitive impairment in Mexican Americans. PLoS ONE 2019, 14, e0213527. [CrossRef] [PubMed]
Liu, J.; Litt, L.; Segal, M.R.; Kelly, M.J.; Pelton, J.G.; Kim, M. Metabolomics of oxidative stress in recent studies of endogenous and
exogenously administered intermediate metabolites. Int. J. Mol. Sci. 2011, 12, 6469–6501. [CrossRef]
Bloomgarden, Z. Diabetes and branched-chain amino acids: What is the link? J. Diabetes 2018, 10, 350–352. [CrossRef]
Zhenyukh, O.; González-Amor, M.; Rodrigues-Diez, R.R.; Esteban, V.; Ruiz-Ortega, M.; Salaices, M.; Mas, S.; Briones, A.M.;
Egido, J. Branched-chain amino acids promote endothelial dysfunction through increased reactive oxygen species generation and
inflammation. J. Cell. Mol. Med. 2018, 22, 4948–4962. [CrossRef]
Wang, Q.; Holmes, M.V.; Davey Smith, G.; Ala-Korpela, M. Genetic Support for a Causal Role of Insulin Resistance on Circulating
Branched-Chain Amino Acids and Inflammation. Diabetes Care 2017, 40, 1779–1786. [CrossRef]
Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D.; Fox, C.S.; Jacques, P.F.; Fernandez, C.; et al.
Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011, 17, 448–453. [CrossRef]
Lauber, C.; Gerl, M.J.; Klose, C.; Ottosson, F.; Melander, O.; Simons, K. Lipidomic risk scores are independent of polygenic risk
scores and can predict incidence of diabetes and cardiovascular disease in a large population cohort. PLoS Biol. 2022, 20, e3001561.
[CrossRef] [PubMed]
Chen, Z.Z.; Gerszten, R.E. Metabolomics and Proteomics in Type 2 Diabetes. Circ. Res. 2020, 126, 1613–1627. [CrossRef] [PubMed]
Hecker, M.; Wagner, A.H. Role of protein carbonylation in diabetes. J. Inherit. Metab. Dis. 2018, 41, 29–38. [CrossRef]
Bollineni, R.C.; Fedorova, M.; Blüher, M.; Hoffmann, R. Carbonylated plasma proteins as potential biomarkers of obesity induced
type 2 diabetes mellitus. J. Proteome Res. 2014, 13, 5081–5093. [CrossRef]
Fu, J.; Luo, Y.; Mou, M.; Zhang, H.; Tang, J.; Wang, Y.; Zhu, F. Advances in Current Diabetes Proteomics: From the Perspectives of
Label- free Quantification and Biomarker Selection. Curr. Drug Targets 2020, 21, 34–54. [CrossRef]
Zhong, W.; Edfors, F.; Gummesson, A.; Bergström, G.; Fagerberg, L.; Uhlén, M. Next generation plasma proteome profiling to
monitor health and disease. Nat. Commun. 2021, 12, 2493. [CrossRef] [PubMed]
Greenwood, C.; Ruff, D.; Kirvell, S.; Johnson, G.; Dhillon, H.S.; Bustin, S.A. Proximity assays for sensitive quantification of
proteins. Biomol. Detect. Quantif. 2015, 4, 10–16. [CrossRef]
Weibrecht, I.; Leuchowius, K.J.; Clausson, C.M.; Conze, T.; Jarvius, M.; Howell, W.M.; Kamali-Moghaddam, M.; Söderberg, O.
Proximity ligation assays: A recent addition to the proteomics toolbox. Expert Rev. Proteom. 2010, 7, 401–409. [CrossRef]
Consortium, R. Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose
Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 2018, 41, 1717–1725. [CrossRef]
American Diabetes Association. Supporting Healthier School Meals. Available online: www.diabetes.org/blog/supportinghealthier-school-meals (accessed on 20 April 2022).
Glycemic. What Is Glycemic Index? Available online: health.clevelandclinic.org/glycemic-index/ (accessed on 20 April 2022).
Berná, G.; Oliveras-López, M.J.; Jurado-Ruíz, E.; Tejedo, J.; Bedoya, F.; Soria, B.; Martín, F. Nutrigenetics and nutrigenomics
insights into diabetes etiopathogenesis. Nutrients 2014, 6, 5338–5369. [CrossRef]
Antioxidants 2022, 11, 1336
17 of 17
109. Felisbino, K.; Granzotti, J.G.; Bello-Santos, L.; Guiloski, I.C. Nutrigenomics in Regulating the Expression of Genes Related to Type
2 Diabetes Mellitus. Front. Physiol. 2021, 12, 699220. [CrossRef]
110. Kang, J.X. Nutrigenomics and systems biology. J. Nutr. Nutr. 2012, 5, I–II. [CrossRef] [PubMed]
111. Shahwan, M.; Alhumaydhi, F.; Ashraf, G.M.; Hasan, P.M.Z.; Shamsi, A. Role of polyphenols in combating Type 2 Diabetes and
insulin resistance. Int. J. Biol. Macromol. 2022, 206, 567–579. [CrossRef] [PubMed]
112. Sun, L.; Miao, M. Dietary polyphenols modulate starch digestion and glycaemic level: A review. Crit. Rev. Food Sci. Nutr. 2020, 60,
541–555. [CrossRef] [PubMed]
113. Mason, S.A.; Keske, M.A.; Wadley, G.D. Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk
Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled
Trials. Diabetes Care 2021, 44, 618–630. [CrossRef] [PubMed]
114. Sekhar, R.V.; McKay, S.V.; Patel, S.G.; Guthikonda, A.P.; Reddy, V.T.; Balasubramanyam, A.; Jahoor, F. Glutathione synthesis is
diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes
Care 2011, 34, 162–167. [CrossRef]
115. Sekhar, R.V. GlyNAC (Glycine and N-Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and
Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study. Antioxidants 2022, 11, 154. [CrossRef]
116. Georgetown. What Is Systems Medicine? Available online: https://systemsmedicine.georgetown.edu/georgetown-difference/
what-is-system-medicine/ (accessed on 2 May 2022).